At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
In Brief
A Phase 2 clinical trial evaluating Psilocybin for Post Traumatic Stress Disorder. Completed, enrolled 22 participants across 3 sites in 2 countries.
Detailed Summary
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Traumatic Stress Disorder
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartJun 2022
Primary CompletionFeb 2024
TodayJul 2026
First PostedApr 5, 2022
Enrollment StartJun 10, 2022
Primary CompletionFeb 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.2 years ago
Interventions
Psilocybindrug
Open label